Pharmacore secures funding to improve medication regimen reviews in long-term care Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader…
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
– Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined…
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
– Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined…
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage…
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage…
Montauk Brewing Company Unveils Two New Branded Spaces at New York Mets’ Citi Field
Montauk Brings Local Flavor to The K Korner at Citi Field with Fan-Favorite Montauk Brewing…
Montauk Brewing Company Unveils Two New Branded Spaces at New York Mets’ Citi Field
Montauk Brings Local Flavor to The K Korner at Citi Field with Fan-Favorite Montauk Brewing…
Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia
Virtual event on Tuesday, May 2, 2023 at 11:00am ET will feature key opinion leader…
Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia
Virtual event on Tuesday, May 2, 2023 at 11:00am ET will feature key opinion leader…
Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update
On track for initial readouts in Q2 2023 from ongoing Phase 1 VYD222 clinical trial…
Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update
On track for initial readouts in Q2 2023 from ongoing Phase 1 VYD222 clinical trial…
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in…
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in…
ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma
SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX…
ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma
SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX…
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and…
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and…
Arch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)
SAWC Spring 2023 represents first clinical conference opportunity to introduce newly effective dedicated AC5 HCPCS…
Arch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)
SAWC Spring 2023 represents first clinical conference opportunity to introduce newly effective dedicated AC5 HCPCS…
HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate
Topline safety and clinical efficacy data from NEST-IN1 expected in the first quarter of 2024…